CPT-11 and cisplatin in the treatment of advanced gastric cancer in Asians

Journal of Chemotherapy

Volumn 15, Issue 4, 2003, Pages 400-405

  Lim, W T ^a   Lim, S T ^a   Wong, N S ^a   Koo, W H ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Advanced gastric cancer; Cisplatin; CPT 11; Palliative chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; ATROPINE; CISPLATIN; DEXAMETHASONE; GRANISETRON; IRINOTECAN; LOPERAMIDE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASIAN; ASTHENIA; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; NEUTROPENIA; STOMACH CANCER; TREATMENT OUTCOME; VOMITING;

EID: 0041846766     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2003.15.4.400     Document Type: Article

References (22)

1. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995; 71(3): 587-91.
2. Glimelius B, Ekstrom K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8(2): 163-8.
3. Glimelius B, Hoffman K, Haglund U, Nyren O, Sjoden PO. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 1994; 5(2): 189-90.
4. Waters JS, Norman A, Cunningham D, et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer 1999; 80(1-2): 269-72.
5. Shirao K, Shimada Y, Kondo H, et al. Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol 1997; 15(3): 921-7.
6. Saltz LB, Spriggs D, Schaaf LJ, et al. Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors. J Clin Oncol 1998; 16(12): 3858-65.
7. Glimelius B, Hoffman K, Graf W, et al. Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol 1995; 6(3): 267-74.
8. Boku N, Ohtsu A, Shimada Y, et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999; 17(1): 319-23.
9. Yoshida M, Boku N, Ohtsu A, Muto M, Nagashima F, Yoshida S. Combination chemotherapy of irinotecan plus cisplatin for advanced gastric cancer: efficacy and feasibility in clinical practice. Gastric Cancer 2001; 4(3): 144-9.
10. Ajani JA, Baker J, Pisters PW, et al. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer 2002; 94(3): 641-6.
11. Yamao T, Kai S, Kazami A, et al. Tumor markers CEA, CA19-9 and CA125 in monitoring of response to systemic chemotherapy in patients with advanced gastric cancer. Jpn J Clin Oncol 1999; 29(11): 550-5.
12. O'Leary J, Muggia FM. Camptothecins: a review of their development and schedules of administration. Eur J Cancer 1998; 34(10): 1500-8.
13. Mathijssen RH, Verweij J, de Jonge MJ, Nooter K, Stoter G, Sparreboom A. Impact of body-size measures on irinotecan clearance: alternative dosing recommendations. J Clin Oncol 2002; 20(1): 81-7.
14. Rivory LP. Metabolism of CPT-11. Impact on activity. Ann N Y Acad Sci 2000; 922: 205-15.
15. Armand JP, Terret C, Couteau C, Rixe O. CPT-11. The European experience. Ann NY Acad Sci 1996; 803: 282-91.
16. Mathijssen RH, van Alphen RJ, Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001; 7(8): 2182-94.
17. Balram C, Sabapathy K, Fei G, Khoo KS, Lee EJ. Genetic polymorphisms of UDP-glucuronosyltransferase in Asians: UGT1A1*28 is a common allele in Indians. Pharmacogenetics 2002; 12(1): 81-3.
18. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 1994; 54(14): 3723-5.
19. Iyer L, Das S, Janisch L, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002; 2(1): 43-7.
20. Ando Y, Ueoka H, Sugiyama T, Ichiki M, Shimokata K, Hasegawa Y. Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan. Ther Drug Monit 2002; 24(1): 111-6.
21. Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000; 60(24): 6921-6.
22. Sato A, Kurihara M, Matsukawa M, et al. Preliminary study of fortnightly irinotecan hydrochloride plus cisplatin therapy in patients with advanced gastric and colorectal cancer. Cancer Chemother Pharmacol 2001; 47(5): 380-4.